Background: Cribriform-morular variant of papillary thyroid carcinoma (CMV-PTC) is a rare tumor that may arise in patients with familial adenomatous polyposis (FAP), although sporadic instances of this tumor have been reported. When it arises in FAP, CMV-PTC may present before colonic manifestations are apparent, so proper identification and classification are essential for prompt assessment of the colonic disease status and genetic and familial counseling. Methods: Nine cases of PTC with cribriform morular cytomorphology were identified at 2 large tertiary-care hospitals; 6 were true CMV-PTC with positive β-catenin and 3 were CMV-like PTC with negative β-catenin. A review of the cytomorphology and a cytology-histology correlation were performed. Results: Only 1 patient presented with a known history of FAP. Patients presented with a median age of 41 years (range 19–64 years). There was a clear female predilection; 8 of 9 patients (89%) were female. All cases demonstrated the classical nuclear and architectural features of PTC. In addition, the most salient features were large tissue fragments with cribriform architecture and dense cellular morules. The elongated cellular shape of the tumor cells led to the misclassification of one tumor as a tall-cell variant of PTC on the FNA material. Conclusion: CMV-PTC or CMV-like PTC demonstrate cytomorphological features that overlap with classic PTC. β-Catenin immunostaining plays an important role in making a definitive diagnosis.

Keywords:
Cytomorphology, Cribriform-morular variant, Papillary thyroid carcinoma, Fine-needle aspiration
1.
Harach HR, Williams GT, Williams ED: Familial adenomatous polyposis associated thyroid carcinoma: a distinct type of follicular cell neoplasm. Histopathology 1994;25:549–561.
2.
Aschebrook-Kilfoy B, Ward MH, Sabra MM, Devesa SS: Thyroid cancer incidence patterns in the United States by histologic type, 1992–2006. Thyroid 2011;21:125–134.
3.
Nosé V: Familial thyroid cancer: a review. Mod Pathol 2011;24:S19–S33.
4.
Tomoda C, Miyauchi A, Uruno T, Takamura Y, Ito Y, Miya A, et al: Cribriform-morular variant of papillary thyroid carcinoma: clue to early detection of familial adenomatous polyposis-associated colon cancer. World J Surg 2004;28:886–889.
5.
Cameselle-Teijeiro J, Ruiz-Ponte C, Loidi L, Suarez-Peñaranda J, Baltar J, Sobrinho-Simoes M: Somatic but not germline mutation of the APC gene in a case of cribriform-morular variant of papillary thyroid carcinoma. Am J Clin Pathol 2001;115:486–493.
6.
Perrier ND, Heerden JAV, Goellner JR, Williams ED, Gharib H, Marchesa P, et al: Thyroid cancer in patients with familial adenomatous polyposis. World J Surg 1998;22:738–743.
7.
Xu B, Yoshimoto K, Miyauchi A, Kuma S, Mizusawa N, Hirokawa M, et al: Cribriform-morular variant of papillary thyroid carcinoma: a pathological and molecular genetic study with evidence of frequent somatic mutations in exon 3 of the beta-catenin gene. J Pathol 2003;199:58–67.
8.
Jung C-K, Choi Y-J, Lee K-Y, Bae J-S, Kim H-J, Yoon S-K, et al: The cytological, clinical, and pathological features of the cribriform-morular variant of papillary thyroid carcinoma and mutation analysis of CTNNB1 and BRAF genes. Thyroid 2009;19:905–913.
9.
Koo JS, Jung W, Hong SW: Cytologic characteristics and beta-catenin immunocytochemistry on smear slide of cribriform-morular variant of papillary thyroid carcinoma. Acta Cytol 2011;55:13–18.
10.
Chong Y, Shin JH, Oh YL, Han B-K, Ko EY: Cribriform-morular variant of papillary thyroid carcinoma: ultrasonographic and clinical characteristics. Thyroid 2012, E-pub ahead of print.
11.
Hirokawa M, Maekawa M, Kuma S, Miyauchi A: Cribriform-morular variant of papillary thyroid carcinoma – cytological and immunocytochemical findings of 18 cases. Diagn Cytopathol 2010;38:890–896.
12.
Chuah KL, Hwang JSG, Ng SB, Tan PH, Poh WT, Au VSC: Cytologic features of cribriform-morular variant of papillary carcinoma of the thyroid: a case report. Acta Cytol 2005;49:75–80.
13.
Kuma S, Hirokawa M, Xu B, Miyauchi A, Kukudo K, Sano T: Cribriform-morular variant of papillary thyroid carcinoma. Report of a case showing morules with peculiar nuclear clearing. Acta Cytol 2004;48:431–436.
14.
Kameyama K, Takami H: FAP associated thyroid carcinoma in mother and her daughter. Fam Cancer 2001;1:83–86.
15.
Inomata M, Ochiai A, Akimoto S, Kitano S, Hirohashi S: Alteration of beta-catenin expression in colonic epithelial cells of familial adenomatous polyposis patients. Cancer Res 1996;56:2213–2217.
16.
Sastre-Perona A, Santisteban P: Role of the Wnt pathway in thyroid cancer. Front Endocrin 2012;3:31.
17.
Syed MI, Stewart M, Syed S, Dahill S, Adams C, McLellan DR, et al: Squamous cell carcinoma of the thyroid gland: primary or secondary disease? J Laryngol Otol 2011;125:3–9.
18.
Bishop JA, Sharma R, Westra WH: PAX8 immunostaining of anaplastic thyroid carcinoma: a reliable means of discerning thyroid origin for undifferentiated tumors of the head and neck. Hum Pathol 2011;42:1873–1877.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.